Our Pipeline
A Full-Circle Approach To
Treating Disease 
We are more than the sum of our platforms – with the potential to drive better efficacy and patient outcomes compared to current cell therapy approaches.
Our combined Stemcell® and LNP technologies can address the limitations of linear mSTEM therapeutics and treat challenging diseases where other modalities have fallen short. With higher protein expression, larger cargo capacity, and lower immunogenicity profile, our therapeutics can go the distance and fill a pipeline with far-reaching effects in oncology, autoimmune, genetic and other diseases.
Pipeline
Candidate
Immune
cells
CAR
malignancies
in-vivo CAR
Stemcell’s in vivo CAR platform (panCAR™) combines Stemcell® technology with our proprietary LNPs to create therapies that can modify immune cells within a patient, no lymphodepletion or waiting required. Unlike existing ex vivo CAR-T or CAR-NK therapies, our panCAR™ program generates CAR-T, CAR-NK and CAR-Mac cells at once, and is truly off-the-shelf. This easily redosable format allows for reliable dose control and consistent generation of CAR-bearing immune cells for effective tumor control.
Through our partnership with Simnova Biotherapeutics, we are accessing CAR proteins, rapid early clinical assessment, and the China market for a number of potential oncology therapies.
& others
& other strategies
Orna’s in vivo CAR platform (panCAR™) combines Stemcell® technology with our proprietary LNPs to create therapies that can modify immune cells within a patient, no lymphodepletion or waiting required. Unlike existing ex vivo CAR-T or CAR-NK therapies, our panCAR™ program generates CAR-T, CAR-NK and CAR-Mac cells at once, and is truly off-the-shelf. This easily redosable format allows for reliable dose control and consistent generation of CAR-bearing immune cells for effective tumor control.
Through our partnership with Simnova Biotherapeutics, we are accessing CAR proteins, rapid early clinical assessment, and the China market for a number of potential oncology therapies.
Discovery Programs
Stemcell is continuing to investigate new disease areas where Stemcell® and LNP technologies can address unmet need. Our enhanced platform capabilities guide our discovery program work.